Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

For Immediate Release

Press Release

Gilead’s Remdesivir Price Is Offensive

Statement of Peter Maybarduk, Director, Public Citizen’s Access to Medicines Program
WASHINGTON -

Note: Gilead today announced that remdesivir, a drug approved to treat COVID-19, will be priced at $3,120 for a typical patient with insurance. Public Citizen previously found that public financial support for remdesivir’s development totals at least $70.5 million, through federal grants and clinical trials, and has pushed for Gilead to price the treatment at $1 per day. Gilead’s price is 10 times higher than the cost-effective benchmark price ($310) suggested by the Institute for Clinical and Economic Review (ICER) last week, given that no mortality benefit has been demonstrated for remdesivir.

In an offensive display of hubris and disregard for the public, Gilead has priced at several thousand dollars a drug that should be in the public domain.

For $1 per day, remdesivir can be manufactured at scale with a reasonable profit. According to ICER, at $310 per course, remdesivir would be cost effective. Gilead has yet to show why the price should be higher. Gilead initially developed remdesivir as one of several candidate treatments for hepatitis C and has made tens of billions off its successful hepatitis C drugs. What is relevant now are Gilead’s as-yet-unpublished costs and the public’s many investments in repurposing remdesivir as a treatment for COVID-19.

Gilead did not make remdesivir alone. Public funding was indispensable at each stage, and government scientists led the early drug discovery team. Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration. The U.S. government has authority and a responsibility to steward the technology it helped develop.

###

Public Citizen full logo

Public Citizen is a nonprofit consumer advocacy organization that champions the public interest in the halls of power. We defend democracy, resist corporate power and work to ensure that government works for the people – not for big corporations. Founded in 1971, we now have 500,000 members and supporters throughout the country.

3 Million People Have Died of Covid Since Rich Nations Began Obstructing Vaccine Patent Waiver

"Every one of those deaths is a mark of shame for the governments of countries like the U.K. and Germany who have protected patents over human lives."

Jake Johnson ·


27 Groups Urge Congress to Close FBI 'Backdoor Search' Loophole

"Ending this unconstitutional practice is imperative to ensure that foreign intelligence surveillance does not swallow Americans' privacy rights."

Brett Wilkins ·



300+ Civil Society Groups Counter-Mobilize Against UN Food Systems Summit

"Repeating the agri-business-as-usual model to solve the food and climate crisis cannot deliver on the holistic and systemic transformation of our food systems we need today."

Kenny Stancil ·


House Dems Ask ExxonMobil Lobbyist to Testify About Climate Misinformation

"For decades, the fossil fuel industry and its allies have used the same tactics as the tobacco industry to spread denial and doubt about the harm of its products," the letter states.

Brett Wilkins ·